Novartis Ag

Ingo Klagge

Christoph Heusser

Gabriela Wochnik-Veltrup

Christoph Schwaerzler

Stefan Hartle

Andrea Polzer

Jose M Carballido Herrera

Josef Prassler

Seth Alexander Ettenberg

Feng Cong

Felix Hartlepp

William Leonard Wishart

José M Carballido Herrera

Adrian Walmsley

Marta Cortes-Cros

Seth Ettenberg

Adrian Robert Walmsley

The present disclosure relates to antibodies targeting LRPand compositions and methods of use thereof.

Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN&#x3b3; production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Anti-IL12R&#x3b2;1 antibodies and their use in treating autoimmune and inflammatory disorders

Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN&#x3b3; production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, and a polynucleotide encoding the binding molecule. The invention also provides an expression vector comprising the polynucleotide, an expression system comprising a polynucleotide capable of producing a binding molecule, as well as an isolated host cell comprising the expression system for producing the binding molecule. The invention also provides for compositions comprising the LINGO binding molecules and the use of binding molecule compositions as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity. The invention further provides for a method of treatment of diseases associated with axonal degeneration and demyelination.

LINGO binding molecules and pharmaceutical use thereof

Growing community of inventors

Neuried, Germany

Ingo Klagge